R&D Rare disease at an inflection point: Why the next wave will ... As rare disease becomes more competitive, information parity is disappearing.
Market Access What rare disease commercialisation in Europe teaches us - a... Rare disease launches are the ultimate stress test for European commercialisation.
R&D Why the government’s latest funding push is critical to the ... Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa
Sales & Marketing Rewiring commercialisation to meet the moment, with Helen Sa... At the Informa Biotech Showcase at JPM2026, EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, discuss new commercialisation.
Digital Cracking the code: How European biotechs can win in the US m... At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for emerging pharma and biotech...
Market Access Consolidating data strategy for global success: Insights fro... At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
